Phenotypic and functional characterization of posoleucel, a multivirus-specific T cell therapy for the treatment and prevention of viral infections in immunocompromised patients.
Spyridoula VasileiouManik KuvalekarYovana VelazquezAyumi WatanabeAnn M LeenSarah A GilmorePublished in: Cytotherapy (2024)
T cells with specificity for posoleucel target viruses and expressing a broad repertoire of T cell receptors. Antigen-driven upregulation of cell-surface molecules and production of cytokine and effector molecules indicative of proliferation, co-stimulation, and cytolytic potential demonstrate the specificity of posoleucel and its potential to mount a broad, polyfunctional, and effective Th1-polarized antiviral response upon viral exposure. We also show the low risk for off-target and nonspecific effects as evidenced by the enrichment of posoleucel in memory T cells, low frequency of naive T cells, and lack of demonstrated alloreactivity in vitro. The efficacy of posoleucel is being explored in four placebo-controlled clinical trials in transplant recipients to treat and prevent viral infections (NCT05179057, NCT05305040, NCT04390113, NCT04605484).
Keyphrases
- sars cov
- cell surface
- clinical trial
- end stage renal disease
- signaling pathway
- newly diagnosed
- ejection fraction
- chronic kidney disease
- placebo controlled
- double blind
- prognostic factors
- cell proliferation
- dendritic cells
- poor prognosis
- peritoneal dialysis
- randomized controlled trial
- risk assessment
- immune response
- human health
- phase iii
- structural basis
- patient reported
- respiratory failure
- extracorporeal membrane oxygenation
- combination therapy
- rectal cancer